Insider Selling: Liquidia (NASDAQ:LQDA) CEO Sells $932,549.12 in Stock

Liquidia Corporation (NASDAQ:LQDA) CEO Roger Jeffs sold 32,744 shares of the business’s stock in a transaction dated Monday, October 12th. The shares were sold at an average price of $28.48, for a total value of $932,549.12. Following the transaction, the chief executive officer owned 1,125,848 shares in the company, valued at $32,064,151.04. This represents a 2.83% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Liquidia Price Performance

Shares of LQDA stock opened at $34.78 on Friday. The stock has a 50 day moving average of $61.21 and a two-hundred day moving average of $61.73. The company has a current ratio of 2.31, a quick ratio of 2.12 and a debt-to-equity ratio of 0.63. Liquidia Corporation has a 12 month low of $21.94 and a 12 month high of $93.61. The company has a market capitalization of $3.11 billion, a P/E ratio of 24.77 and a beta of 0.61.

Liquidia (NASDAQ:LQDA) last announced its quarterly earnings data on Wednesday, August 12th. The company reported $0.74 earnings per share for the quarter, missing the consensus estimate of $0.76 by ($0.02). The firm had revenue of $171.68 million for the quarter, compared to analyst estimates of $168.48 million. Liquidia had a return on equity of 149.65% and a net margin of 30.74%. Liquidia’s revenue for the quarter was up 1842.1% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.49) EPS. As a group, equities analysts expect that Liquidia Corporation will post 2.05 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the stock. Wedbush set a $58.00 price target on shares of Liquidia in a report on Friday, October 2nd. Piper Sandler set a $129.00 price objective on shares of Liquidia in a research note on Friday, July 24th. Wells Fargo & Company raised their price objective on shares of Liquidia from $30.00 to $33.00 and gave the stock an “equal weight” rating in a report on Wednesday. Needham & Company LLC decreased their target price on shares of Liquidia from $72.00 to $58.00 and set a “buy” rating on the stock in a research report on Wednesday. Finally, Jefferies Financial Group upgraded shares of Liquidia to a “strong-buy” rating in a research report on Thursday, October 1st. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, four have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, Liquidia currently has a consensus rating of “Hold” and an average price target of $72.85.

Hedge Funds Weigh In On Liquidia

Several hedge funds and other institutional investors have recently modified their holdings of LQDA. Globeflex Capital L P acquired a new stake in Liquidia in the 2nd quarter valued at $175,000. Nykredit A S acquired a new position in Liquidia during the second quarter worth $177,000. Fluent Financial LLC acquired a new position in Liquidia during the second quarter worth $287,000. WINTON GROUP Ltd acquired a new position in Liquidia during the second quarter worth $335,000. Finally, Fulcrum Equity Management acquired a new position in Liquidia during the second quarter worth $399,000. Institutional investors own 64.54% of the company’s stock.

Liquidia News Roundup

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Liquidia settled all six patent and antitrust disputes with United Therapeutics for a net $380.7 million, allowing continued commercialization of YUTREPIA for pulmonary arterial hypertension. Ending the litigation removes significant legal uncertainty and avoids a potentially market-disrupting appeal. Liquidia shares surge as settlement ends United Therapeutics litigation
• Positive Sentiment: Analyst sentiment improved after the settlement. LifeSci Capital upgraded LQDA to “outperform” with a $59 price target, while HC Wainwright raised its target to $65 and initiated or reiterated a “buy” rating. BTIG also upgraded the stock to “buy” with a $70 target. LifeSci Capital upgrades Liquidia
• Positive Sentiment: Preliminary third-quarter YUTREPIA net product sales were reported at $222.7 million. Management expects existing cash and ongoing sales to fund the settlement and planned clinical programs without requiring additional financing, supporting the investment case if commercial momentum continues.
• Positive Sentiment: Trading activity reflected renewed speculative interest, with call-option volume more than doubling its typical level. This suggests some traders are positioning for additional gains following the legal resolution.
• Neutral Sentiment: Multiple executives and insiders, including the CEO and CFO, sold shares at $28.48 under pre-arranged Rule 10b5-1 plans to cover tax obligations on vested equity awards. Because the transactions were planned and sellers retained substantial holdings, they are a limited standalone signal of sentiment. Liquidia insider sale filing
• Negative Sentiment: The $380.7 million settlement will require $175 million within 30 business days, $145.4 million in 2027 installments and $60.3 million tied to antitrust litigation. These payments could materially reduce Liquidia’s cash cushion and constrain future investment.
• Negative Sentiment: Liquidia agreed not to appeal the infringement ruling and will remove the PH-ILD indication from YUTREPIA’s label, narrowing the drug’s addressable market. Needham lowered its price target to $58, despite maintaining a “buy” rating, highlighting ongoing execution and valuation risks.

Liquidia Company Profile

Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing therapies for patients with serious cardiopulmonary diseases and other rare conditions. The company uses its proprietary PRINT technology to engineer drug particles with controlled size, shape and composition, with the goal of improving the delivery and performance of medicines.

Liquidia’s lead product is Yutrepia (treprostinil) inhalation powder, a dry-powder inhaler designed for the treatment of pulmonary arterial hypertension (PAH).